moxonidine has been researched along with Cardiomegaly in 3 studies
moxonidine: structure given in first source
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moxonidine is a second-generation, centrally acting antihypertensive drug with a distinctive mode of action." | 2.39 | Pharmacology of moxonidine, an I1-imidazoline receptor agonist. ( Ernsberger, P; Haxhiu, MA; Kaan, EC; Papp, JG; Ziegler, D, 1996) |
| "Pretreatment with efaroxan (a selective I(1)-imidazoline receptor antagonist) or rauwolscine (a selective alpha(2)-adrenoceptor antagonist) inhibited the moxonidine-induced increases in ANP secretion and interstitial ANP concentration and decrease in pulse pressure." | 1.32 | Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy. ( Cao, C; Kang, CW; Kim, SH; Kim, SZ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, C | 1 |
| Kang, CW | 1 |
| Kim, SZ | 1 |
| Kim, SH | 1 |
| Ziegler, D | 1 |
| Haxhiu, MA | 1 |
| Kaan, EC | 1 |
| Papp, JG | 1 |
| Ernsberger, P | 1 |
| Van Kerckhoven, R | 1 |
| van Veen, TA | 1 |
| Boomsma, F | 1 |
| Saxena, PR | 1 |
| Schoemaker, RG | 1 |
1 review available for moxonidine and Cardiomegaly
| Article | Year |
|---|---|
Pharmacology of moxonidine, an I1-imidazoline receptor agonist.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Cats; Dogs; Heart Rate; Hypertension | 1996 |
2 other studies available for moxonidine and Cardiomegaly
| Article | Year |
|---|---|
Augmentation of moxonidine-induced increase in ANP release by atrial hypertrophy.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Atrial Fu | 2004 |
Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model.
Topics: Animals; Blood Pressure; Cardiomegaly; Catecholamines; Collagen; Disease Models, Animal; Dose-Respon | 2000 |